582 related articles for article (PubMed ID: 1922207)
41. Do prognostic parameters of remission versus relapse after Bacillus Calmette-Guérin (BCG) immunotherapy exist?. analysis of a quarter century of literature.
Saint F; Salomon L; Quintela R; Cicco A; Hoznek A; Abbou CC; Chopin DK
Eur Urol; 2003 Apr; 43(4):351-60; discussion 360-1. PubMed ID: 12667715
[TBL] [Abstract][Full Text] [Related]
42. Prognostic value of Bcl-2 and Bax tumor cell expression in patients with non muscle-invasive bladder cancer receiving bacillus Calmette-Guerin immunotherapy.
Ajili F; Kaabi B; Darouiche A; Tounsi H; Kourda N; Chebil M; Manai M; Boubaker S
Ultrastruct Pathol; 2012 Feb; 36(1):31-9. PubMed ID: 22292735
[TBL] [Abstract][Full Text] [Related]
43. Factors affecting valrubicin response in patients with bacillus Calmette-Guérin-refractory bladder carcinoma in situ.
Steinberg GD; Smith ND; Ryder K; Strangman NM; Slater SJ
Postgrad Med; 2011 May; 123(3):28-34. PubMed ID: 21566413
[TBL] [Abstract][Full Text] [Related]
44. [ImmuCyst intravesical (freeze-dried preparation made from the connaught strain of Bacillus Calmette Guérin) for the treatment of superficial bladder cancer and carcinoma in situ of urinary bladder].
Tsukagoshi S
Gan To Kagaku Ryoho; 2003 Jul; 30(7):1027-38. PubMed ID: 12894724
[TBL] [Abstract][Full Text] [Related]
45. The effects of intravesical chemoimmunotherapy with epirubicin and bacillus Calmette-Guérin for prophylaxis of recurrence of superficial bladder cancer: a preliminary report.
Uekado Y; Hirano A; Shinka T; Ohkawa T
Cancer Chemother Pharmacol; 1994; 35 Suppl():S65-8. PubMed ID: 7994790
[TBL] [Abstract][Full Text] [Related]
46. [Initial clinical studies of the preparation Immucyst for immunotherapy in patients with carcinoma in situ (CIS) of the bladder].
Ormanov I; Kumanov Kh; Panchev P; Kirilov S; Filev A; Ianev K; Maki D
Khirurgiia (Sofiia); 1994; 47(3):11-2. PubMed ID: 8531421
[TBL] [Abstract][Full Text] [Related]
47. Intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer: effect of bacillus Calmette-Guerin viability on treatment results.
Kelley DR; Ratliff TL; Catalona WJ; Shapiro A; Lage JM; Bauer WC; Haaff EO; Dresner SM
J Urol; 1985 Jul; 134(1):48-53. PubMed ID: 3892051
[TBL] [Abstract][Full Text] [Related]
48. Bacillus Calmette-Guerin immunotherapy for bladder cancer.
Lamm DL
J Urol; 1985 Jul; 134(1):40-7. PubMed ID: 3892050
[TBL] [Abstract][Full Text] [Related]
49. The efficiency of the EORTC scoring system for the prediction of recurrence and progression of non-muscle-invasive bladder cancer treated by bacillus Calmette-Guerin immunotherapy.
Ajili F; Darouiche A; Chebil M; Boubaker S
Ultrastruct Pathol; 2013 Aug; 37(4):249-53. PubMed ID: 23899093
[TBL] [Abstract][Full Text] [Related]
50. Editor's choice: Implications of isoniazid resistance in Mycobacterium bovis Bacillus Calmette-Guérin used for immunotherapy in bladder cancer.
Watts MR; Taylor PC; Sintchenko V; Whelan CM; Farnsworth RH; Jones P; Jelfs P; Carr D; Goldberg H
Clin Infect Dis; 2011 Jan; 52(1):86-8. PubMed ID: 21148524
[TBL] [Abstract][Full Text] [Related]
51. Possible factors affecting response to intravesical bacillus Calmette-Guérin (Tokyo 172 strain) therapy for carcinoma in situ of the bladder: a multivariate analysis.
Takashi M; Katsuno S; Yuba H; Ohshima S; Wakai K; Ohno Y
Int Urol Nephrol; 1998; 30(6):713-22. PubMed ID: 10195866
[TBL] [Abstract][Full Text] [Related]
52. Long-term results of intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer.
Sarosdy MF; Lamm DL
J Urol; 1989 Sep; 142(3):719-22. PubMed ID: 2769847
[TBL] [Abstract][Full Text] [Related]
53. Bilateral panuveitis following intravesical BCG immunotherapy for bladder carcinoma.
Uppal GS; Shah AN; Tossounis CM; Tappin MJ
Ocul Immunol Inflamm; 2010 Aug; 18(4):292-6. PubMed ID: 20662661
[TBL] [Abstract][Full Text] [Related]
54. New agents for bacillus Calmette-Guérin-refractory nonmuscle invasive bladder cancer.
Ahn JJ; Ghandour RA; McKiernan JM
Curr Opin Urol; 2014 Sep; 24(5):540-5. PubMed ID: 24921906
[TBL] [Abstract][Full Text] [Related]
55. Long-term effect of intravesical bacillus Calmette-Guerin on flat carcinoma in situ of the bladder.
Herr HW; Pinsky CM; Whitmore WF; Sogani PC; Oettgen HF; Melamed MR
J Urol; 1986 Feb; 135(2):265-7. PubMed ID: 3511284
[TBL] [Abstract][Full Text] [Related]
56. 15-year experience on intravesical therapy of T1G3 urinary bladder cancer: a conservative approach.
Cheng CW; Chan SF; Chan LW; Chan CK; Ng CF; Cheung HY; Chan SY; Wong WS; Lai FM; Li ML
Jpn J Clin Oncol; 2004 Apr; 34(4):202-5. PubMed ID: 15121756
[TBL] [Abstract][Full Text] [Related]
57. Bacillus Calmete-Guérin plus interferon-alpha2B intravesical therapy maintains an extended treatment plan for superficial bladder cancer with minimal toxicity.
Lam JS; Benson MC; O'Donnell MA; Sawczuk A; Gavazzi A; Wechsler MH; Sawczuk IS
Urol Oncol; 2003; 21(5):354-60. PubMed ID: 14670544
[TBL] [Abstract][Full Text] [Related]
58. Immunotherapy of bladder cancer.
Nseyo UO; Lamm DL
Semin Surg Oncol; 1997; 13(5):342-9. PubMed ID: 9259090
[TBL] [Abstract][Full Text] [Related]
59. The management of superficial bladder tumors and carcinoma in situ with intravesical bacillus Calmette-Guerin.
deKernion JB; Huang MY; Lindner A; Smith RB; Kaufman JJ
J Urol; 1985 Apr; 133(4):598-601. PubMed ID: 3981707
[TBL] [Abstract][Full Text] [Related]
60. Bacillus Calmette-Guerin (BCG) in the treatment of superficial bladder cancer.
Cheng C; Consigliere D; Foo KT; Tan EC; Tung KH; Tock EP
Ann Acad Med Singap; 1995 Jul; 24(4):562-5. PubMed ID: 8849189
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]